



Published in final edited form as:

*Chem Commun (Camb)*. 2014 October 11; 50(79): 11679–11682. doi:10.1039/c4cc02969k.

## Storable *N*-Phenylcarbamate Palladacycles for Rapid Functionalization of An Alkyne-Encoded Protein

Gang Cheng, Reyna K. V. Lim, Carlo P. Ramil, and Qing Lin

Department of Chemistry, State University of New York at Buffalo, Buffalo, New York 14260, USA. Fax: +1 (716) 6456963; Tel: +1 (716) 645 4254

Qing Lin: qinglin@buffalo.edu

### Abstract

Here we report the synthesis of storable *N*-phenyl-carbamate palladacycles that showed robust reactivity in the cross-coupling reaction with an alkyne-encoded protein with second-order rate constant approaching  $19\,770 \pm 930\text{ M}^{-1}\text{ s}^{-1}$ .

Because of their excellent functional group tolerance and compatibility with biological systems, palladium-mediated cross coupling reactions have attracted a lot of interests recently as a bioconjugation tool both in vitro and in vivo.<sup>1–5</sup> For example, we reported the development of the palladium–*N,N*-dimethylamino-pyrimidine complex mediated Sonogashira cross-coupling for selective functionalization of a homopropargylglycine (Hpg)-encoded protein (Ub-Hpg) in aqueous medium and inside *E. coli* cells.<sup>6</sup> Chen and co-workers reported the ligand-free Pd(NO<sub>3</sub>)<sub>2</sub>-mediated Sonogashira cross-coupling and its application in labeling an alkyne-encoded protein in gram-negative *Shigella* bacteria.<sup>7</sup> In both cases, a two-step ‘pre-activation’ procedure was employed in which the arylpalladium(II) complex was formed in situ prior to incubation with the alkyne-encoded proteins. While the reactions were generally clean, the arylpalladium(II) complexes were unstable and prone to decompose over time in PBS buffer. As an alternative strategy, Myers and co-workers reported the preparation of storable arylpalladium(II) complexes through decarboxylative palladation and the use of the complexes in Heck-type bioconjugation reactions in aqueous medium.<sup>8</sup> Inspired by this work, we turned our attention to identify stable, yet reactive, palladium complexes for selectively functionalizing the alkyne-encoded proteins.

Palladacycles are usually identified as the reactive intermediates in palladium-mediated reactions<sup>9</sup>, including C-H functionalization reactions,<sup>10, 11</sup> and have been used as precatalysts,<sup>12–14</sup> sensors,<sup>15</sup> chiral auxiliaries, optical, and electronic devices.<sup>16</sup> Recently, we reported the first example of using the acetanilide palladacycles to functionalize the Hpg-encoded ubiquitin protein (Ub-Hpg).<sup>17</sup> These palladacycles exhibited improved stability and good ligation efficiency with the Ub-Hpg compared with the in situ generated arylpalladium(II) complex.<sup>6, 7</sup> However, the conversions were modest for palladacycles

Correspondence to: Qing Lin, qinglin@buffalo.edu.

†Electronic Supplementary Information (ESI) available. See DOI: 10.1039/c000000x/

containing BODIPY or fluorescein fluorophore. For in vivo applications, the low concentrations of the alkyne-encoded substrates (usually nM to low  $\mu$ M) demands high bioconjugation efficiency.<sup>18, 19</sup> Herein, we report the discovery of the *N*-phenyl-carbamate palladacycles for robust cross-coupling with a terminal alkyne-encoded protein. To our knowledge, this is the first report of this type of palladacycles and their use as storable organometallic reagents for biological applications.

Our previously study showed the acetanilide palladacycles. e.g., **1** and **2** in Table 1, were stable in PBS, yet retained selective ligation reactivity to alkyne group.<sup>17</sup> We reasoned that this reactivity can be enhanced through the use of a proper directing group. We prepared a panel of new palladacycles carrying the various directing groups (Table 1). The pivaloylanilide palladacycle **3**,<sup>20</sup> the phenylurea palladacycle **4**,<sup>21, 22</sup> the phenol ester palladacycle **5**,<sup>23</sup> and the *O*-phenylcarbamate palladacycle **6**<sup>24</sup> were prepared according to the published procedures. On the other hand, the *N*-phenylcarbamate palladacycles **7–20** were prepared by treating the corresponding carbamate with Pd(OAc)<sub>2</sub> and triflic acid in dichloroethane or dioxane at room temperature (see Table S1 in the Supplemental Information for yields).

With these palladacycles in hand, we examined their reactivity in the bioconjugation reaction with Ub-Hpg (Table 1). Compared to acetanilide palladacycle **1** (entry 1),<sup>17</sup> pivaloylanilide palladacycle **3** (entry 3) and *N*-phenylurea palladacycle **4** (entry 4) gave similar conversions while the ester and carbamate palladacycles **5–8** (entries 5–8) gave significantly higher conversions at 30 sec (Table 1). Extending the reaction time to 3 min led to quantitative conversion for *N*-phenyl-carbamate palladacycles **7–8** (entries 7, 8), comparable to the most reactive acetanilide palladacycle **2** (entry 2) reported previously.<sup>17</sup> Interestingly, *N*-phenylcarbamate palladacycle **7** showed higher reactivity than the isomeric *O*-phenylcarbamate palladacycle **6**, indicating a subtle effect of the directing group. Notably, for the most reactive palladacycles **7** and **8**, the ubiquitin dimer side products from consecutive alkyne insertion reactions (see Table 1 footnote for a possible structure) were not observed,<sup>25</sup> suggesting that the vinyl palladium intermediates containing the *N*-phenylcarbamate directing group are stable before reductive depalladation to generate the styrenyl products.<sup>17</sup> Among the palladacycles, the *N*-phenylcarbamate palladacycles clearly offer the fastest and clean reactions with the alkyne-containing protein substrate in PBS buffer.

Next, we evaluated the stability of the *N*-phenylcarbamate palladacycles. To our satisfaction, all palladacycles showed excellent stability in the deuterated PBS buffer containing 5% DMSO-*d*<sub>6</sub> after incubation at room temperature for 24 hours as monitored by <sup>1</sup>H NMR (Table S2 and Figure S1).

Then, we synthesized a series of *N*-phenylcarbamate palladacycle derivatives and evaluated their reactivities in the bioconjugation reaction with the alkyne-encoded protein, Ub-Hpg (Table 2). To our delight, essentially all palladacycles afforded the desired cross-coupling products in quantitative conversion after 3 min (11 entries out of 12 in Table 1). The styrenyl conjugate structure<sup>26</sup> from palladacycle **9** was assigned based on the trypsin digestion/LC-MS analysis of the product (Figure S2). Variation of the *O*-alkyl group at the

carbamate moiety minimally affected the reactivity (compare entries 1–3 in Table 2 to entry 7 in Table 1). For *N*-phenyl ring, substitution with the strong electron-donating methoxy group decreased the reaction rate as reflected by the reduced conversion at 10 sec (compare entries 4–5 in Table 2 to entry 7 in Table 1; entry 6 to 1 in Table 2), while substitution of the methyl group (entries 7–8) and the fluorine at the *para*-position (entry 9) had a minimum effect. However, substitution of fluorine at the *meta*-position (entry 10) and chlorine at the *para*-position (entry 11) slowed down the reactions. Interestingly, palladacycles **20** containing a BODIPY moiety at the *para*-position slowed down the reaction together with a significantly reduced conversion at 3 min (entry 12), suggesting that the large BODIPY group hinders the cross-coupling reaction.

Since the difference in reactivity appears mainly to be a kinetic effect (Tables 1 and 2), we determined the second-order rate constant,  $k_2$ , of *N*-phenylcarbamate palladacycle **9** in the cross-coupling reaction and compared it with acetanilide palladacycles **1** and **2** we synthesized previously<sup>17</sup> (Figure 1). Palladacycle **9** afforded a  $k_2$  value of  $19\,770 \pm 930 \text{ M}^{-1} \text{ s}^{-1}$ , more than three times faster than *N*-naphthylacetanilide **2** ( $k_2 = 5\,764 \pm 318 \text{ M}^{-1} \text{ s}^{-1}$ ) and 35 times faster than acetanilide **1** ( $k_2 = 559 \pm 33 \text{ M}^{-1} \text{ s}^{-1}$ ) (Figure 1). Since the palladacycles were used in excess in the reaction, the accelerated rate for the carbamate palladacycle **9** can be attributed to more efficient alkyne insertion into the aryl-palladium bond, leading to accelerated formation of the vinyl palladium intermediate.<sup>17</sup>

To verify the high reactivity and selectivity of the *N*-phenyl-carbamate palladacycles in the bioconjugation reaction with Ub-Hpg, we performed the SDS-PAGE/in-gel fluorescence analyses of the reactions involving the BODIPY-modified *N*-phenylcarbamate palladacycle **20** and acetanilide palladacycle **22**.<sup>17</sup> As shown in Figure 2a, palladacycle **20** showed a visible fluorescent adduct with Ub-Hpg (lane 5), but not wild-type Ub (lane 2), whereas palladacycle **22** did not show any adduct formation (lane 6) under the identical conditions, indicating a higher reactivity and selectivity for palladacycle **20**. Similarly, the reaction of an mPEG-containing palladacycle **21** with Ub-Hpg gave the PEGylated product in 70% conversion after 1 min based on densitometry, significantly higher than that of a mPEG-containing acetanilide palladacycle **23**<sup>17</sup> (10% conversion; Figure 2b). No PEGylated adduct was observed for the wild-type Ub under the same condition (lane 1), indicating the palladacycle-mediated conjugation is highly selective toward the terminal alkyne group.

In summary, we have synthesized a new class of storable palladacycles from the *N*-phenylcarbamates. These palladacycles showed excellent stability in phosphate buffered saline and superior reactivity in selectively functionalizing the terminal alkyne-encoded protein *via* the Heck-type cross-coupling reaction. The kinetic measurement revealed an extremely fast bioconjugation reaction, with the second-order rate constant approaching  $19\,770 \text{ M}^{-1} \text{ s}^{-1}$ . This rate constant is significantly greater than that of the copper-catalysed azide-alkyne cycloaddition ( $10\text{--}200 \text{ M}^{-1} \text{ s}^{-1}$  in the presence of  $10\text{--}500 \mu\text{M}$  of  $\text{Cu}^{\text{I}}$ ),<sup>27</sup> on par with the fastest photoclick chemistry ( $k_2 = 10\,420 \text{ M}^{-1} \text{ s}^{-1}$ ),<sup>28</sup> but slower than the fastest tetrazine ligation ( $k_2 = 2.8 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ ).<sup>29</sup> We also demonstrated the suitability of the *N*-phenylcarbamate palladacycles in selectively functionalizing the alkyne-encoded proteins with a fluorophore and a PEG in biological buffer. Since the preparation of the palladacycles requires the use of stoichiometric amount of triflic acid or tosylic acid, the acid-sensitive

functional groups are not tolerated in the palladacycle structure. The continuous investigation of the scope of the palladacycles containing other types of biophysical and biochemical probes such as biotin<sup>30</sup> and the unprotected carbohydrates as well as the compatibility of this class of organometallic reagents with living systems are currently underway.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

We gratefully acknowledge the National Institutes of Health (GM 085092) and the National Science Foundation (CHE-1305826) for financial support. The FT-ICR mass spectrometer used in this study was supported through a grant from the NIH National Center for Research Resources (S10RR029517)


## Notes and references

1. Ramil CP, Lin Q. *Chem Commun.* 2013; 49:11007–11022.
2. Ojida A, Tsutsumi H, Kasagi N, Hamachi I. *Tetrahedron Lett.* 2005; 46:3301–3305.
3. (a) Kodama K, Fukuzawa S, Nakayama H, Kigawa T, Sakamoto K, Yabuki T, Matsuda N, Shirouzu M, Takio K, Tachibana K, Yokoyama S. *ChemBioChem.* 2006; 7:134–139. [PubMed: 16307466] (b) Kodama K, Fukuzawa S, Nakayama H, Sakamoto K, Kigawa T, Yabuki T, Matsuda N, Shirouzu M, Takio K, Yokoyama S, Tachibana K. *ChemBioChem.* 2007; 8:232–238. [PubMed: 17195252] (c) Tilley SD, Francis MB. *J Am Chem Soc.* 2006; 128:1080–1081. [PubMed: 16433516] (d) Brustad E, Bushey ML, Lee JW, Groff D, Liu W, Schultz PG. *Angew Chem Int Ed.* 2008; 47:8220–8223. (e) Ourailidou ME, van der Meer JY, Baas BJ, Jeronimus-Stratingh M, Gottumukkala AL, Poelarends GJ, Minnaard AJ, Dekker FJ. *ChemBioChem.* 2014; 15:209–212. [PubMed: 24376051]
4. (a) Yusop RM, Unciti-Broceta A, Johansson EM, Sanchez-Martin RM, Bradley M. *Nat Chem.* 2011; 3:239–243. [PubMed: 21336331] (b) Li J, Yu J, Zhao J, Wang J, Zheng S, Lin S, Chen L, Yang M, Jia S, Zhang X, Chen PR. *Nat Chem.* 2014; 6:352–361. [PubMed: 24651204]
5. (a) Chalker JM, Wood CSC, Davis BG. *J Am Chem Soc.* 2009; 131:16346–16347. [PubMed: 19852502] (b) Spicer CD, Davis BG. *Chem Commun.* 2011; 47:1698–1700. (c) Spicer CD, Triemer T, Davis BG. *J Am Chem Soc.* 2012; 134:800–803. [PubMed: 22175226] (d) Spicer CD, Davis BG. *Chem Commun.* 2013; 49:2747–2749. (e) Dumas A, Spicer CD, Gao Z, Takehana T, Lin YA, Yasukohchi T, Davis BG. *Angew Chem Int Ed.* 2013; 52:3916–3921. (f) Lercher L, McGouran JF, Kessler BM, Schofield CJ, Davis BG. *Angew Chem Int Ed.* 2013; 52:10553–10558. (g) Gao Z, Gouverneur V, Davis BG. *J Am Chem Soc.* 2013; 135:13612–13615. [PubMed: 23991754]
6. Li N, Lim RK, Edwardraja S, Lin Q. *J Am Chem Soc.* 2011; 133:15316–15319. [PubMed: 21899368]
7. Li J, Lin S, Wang J, Jia S, Yang M, Hao Z, Zhang X, Chen PR. *J Am Chem Soc.* 2013; 135:7330–7338. [PubMed: 23641876]
8. Simmons RL, Yu RT, Myers AG. *J Am Chem Soc.* 2011; 133:15870–15873. [PubMed: 21888420]
9. Dyker G. *Chem Ber.* 1997; 130:1567–1578.
10. Engle KM, Mei TS, Wasa M, Yu JQ. *Acc Chem Res.* 2012; 45:788–802. [PubMed: 22166158]
11. Lyons TW, Sanford MS. *Chem Rev.* 2010; 110:1147–1169. [PubMed: 20078038]
12. Dupont J, Consorti CS, Spencer J. *Chem Rev.* 2005; 105:2527–2571. [PubMed: 15941221]
13. Yang Y, Oldenhuis NJ, Buchwald SL. *Angew Chem Int Ed.* 2013; 52:615–619.
14. Herrmann WA, Brossmer C, Öfele K, Reisinger CP, Priermeier T, Beller M, Fischer H. *Angew Chem Int Ed.* 1995; 34:1844–1848.
15. Michel BW, Lippert AR, Chang CJ. *J Am Chem Soc.* 2012; 134:15668–15671. [PubMed: 22970765]


16. Dupont, J.; Pfeffer, M. *Palladacycles-Synthesis, Characterization and Application*. 1. Wiley-VCH Verlag GmbH & Co; Weinheim, Germany: 2008.
17. Cheng G, Lim RK, Li N, Lin Q. *Chem commun.* 2013; 49:6809–6811.
18. Bertozzi CR. *Acc Chem Res.* 2011; 44:651–653. [PubMed: 21928847]
19. Sletten EM, Bertozzi CR. *Angew Chem Int Ed.* 2009; 48:6974–6998.
20. Yeung CS, Zhao X, Borduas N, Dong VM. *Chem Sci.* 2010; 1:331–336.
21. Houlden CE, Hutchby M, Bailey CD, Ford JG, Tyler SN, Gagne MR, Lloyd-Jones GC, Booker-Milburn KI. *Angew Chem Int Ed.* 2009; 48:1830–1833.
22. Rauf W, Thompson AL, Brown JM. *Chem Commun.* 2009:3874–3876.
23. Xiao B, Fu Y, Xu J, Gong TJ, Dai JJ, Yi J, Liu L. *J Am Chem Soc.* 2010; 132:468–469. [PubMed: 20020760]
24. John A, Nicholas KM. *J Org Chem.* 2012; 77:5600–5605. [PubMed: 22663545]
25. Bahoun A, Dehand J, Pfeffer M, Zinsius M, Bouaoud S-E, Le Borgne G. *J Chem Soc, Dalton Trans.* 1979:547–556.
26. The *trans*-alkene structure was assigned based on the consideration of the sterics during the alkyne insertion step; see: Larock RC, Yum EK, Refvik MD. *J Org Chem.* 1998; 63:7652–7662.
27. Lang K, Chin JW. *ACS Chem Biol.* 2014; 9:16–20. [PubMed: 24432752]
28. Yu Z, Lin Q. *J Am Chem Soc.* 2014; 136:4153–4156. [PubMed: 24592808]
29. Rossin R, van den Bosch SM, Ten Hoeve W, Carvelli M, Versteegen RM, Lub J, Robillard MS. *Bioconjug Chem.* 2013; 24:1210–1217. [PubMed: 23725393]
30. In our preliminary studies, a biotin-containing palladacycle can be readily prepared; see Figure S3 in the ESI for details.



**Figure 1.** Kinetics characterization of palladacycles **1**, **2** and **9** in the bioconjugation reaction with Ub-Hpg. The reactions were set up by incubating 2.5  $\mu\text{M}$  Ub-Hpg with 10  $\mu\text{M}$  palladacycle in PBS at room temperature, and the conversions were determined by LC-MS. The plots were fitted with the one-phase decay equation in GraphPad Prism to derive the pseudo-first-order rate constant,  $k_1$ . The second-order rate constant was calculated using the equation:  $k_2 = k_1 / [\text{palladacycle}]$ .




**Figure 2.** Reactivity comparison of the *N*-phenylcarbamate palladacycles vs. the acetanilide palladacycles in the bioconjugation reaction with Ub-Hpg. (a) Coomassie blue stained SDS-PAGE (top) and in-gel fluorescence analysis (bottom) of the product mixture after incubating 2.5  $\mu$ M Ub-Hpg with 10  $\mu$ M palladacycle **20** or **22** in PBS for 1 min;  $\lambda_{\text{ex}} = 365$  nm. The fluorescent labeled product band is indicated with an arrow. The front migrating excess palladacycles are indicated with an asterisk. 15% SDS-PAGE gel was used. (b) Coomassie blue stained SDS-PAGE gel of the PEGylation product mixtures after incubating 2.5  $\mu$ M Ub-Hpg with 10  $\mu$ M palladacycle **21** or **23** in PBS for 1 min. The PEGylated product band is indicated with an arrow. Bio-Rad Any kD Mini-PROTEAN TGX Gel was used.

**Table 1**Reactivity of Palladacycles Carrying the Various Directing Groups toward Ub-Hpg<sup>a</sup>

entry	palladacycle	conversion (%) <sup>b</sup>	
		10 s	3 min
1		7	83 (3) <sup>c</sup>
2		48	>99
3		9	65 (25) <sup>c</sup>
4		10	85 (10) <sup>c</sup>
5		56	94 (6) <sup>c</sup>
6		40	87 (11) <sup>c</sup>
7		73	>99






entry	palladacycle	conversion (%) <sup>b</sup>	
		10 s	3 min
8	 <b>8</b>	64	>99


<sup>a</sup>Reaction was carried out by incubating 2.5  $\mu\text{M}$  Ub-Hpg with 10  $\mu\text{M}$  palladacycle at room temperature for the indicated time (see detail procedure in SI, general procedures for the reaction of palladacycles with Ub-Hpg).

<sup>b</sup>Conversion was determined based on LC-MS analysis: conversion % =  $I_{\text{product}} / (I_{\text{Ub-Hpg}} + I_{\text{product}} + I_{\text{dimer side product}} \times 2)$ , where  $I_{\text{Ub-Hpg}}$ ,  $I_{\text{product}}$  and  $I_{\text{dimer side product}}$  represent the ion counts of Ub-Hpg, product and the protein dimer side product, respectively.

<sup>c</sup>Value in parenthesis denotes the conversion of the dimer side product. The mass of the dimer side product is consistent with the structure: ; see ref. 25 for a possible mechanism.

**Table 2**Reactivity of Substituted *N*-Phenylcarbamate Palladacycles toward Ub- Hpg<sup>a</sup>

entry	palladacycles	conversion (%) <sup>b</sup>	
		10 s	3 min
1		83	>99
	<b>9</b>		
2		71	>99
	<b>10</b>		
3		79	97
	<b>11</b>		
4		42	>99
	<b>12</b>		
5		40	>99
	<b>13</b>		
6		49	>99
	<b>14</b>		
7		74	>99
	<b>15</b>		
8		80	>99
	<b>16</b>		



entry	palladacycles	conversion (%) <sup>b</sup>	
		10 s	3 min
9	 17	74	>99
10	 18	35	>99
11	 19	41	>99
12	 20	41	53

<sup>a</sup>Reaction was carried out by incubating 2.5 μM Ub-Hpg with 10 μM palladacycle at room temperature for the indicated time (see detail procedure in SI, general procedures for the reaction of palladacycles with Ub-Hpg).

<sup>b</sup>Conversion was determined based on LC-MS analysis: conversion % =  $I_{\text{product}} / (I_{\text{Ub-Hpg}} + I_{\text{product}})$ , where  $I_{\text{Ub-Hpg}}$  and  $I_{\text{product}}$  represent the ion counts of Ub-Hpg and the product, respectively.